Over $1.75/Share We Go TODAY!, page-110

This just out from WALL STREET Journal...

"Congress member Tom Price, Donald Trump’s pick to run the Department of Health and Human Services, has been under fire for trading health care stocks while writing laws that impacted the companies he was investing in. And now, according to the Wall Street Journal’s James Grimaldi, it looks like he may have doubled his trouble by not being entirely accurate in his statements to Congress during his two rounds of confirmation hearings.

What’s at issue specifically is his purchase of discounted shares in an Australian biotechnology company called Innate Immunotherapeutics. During Senate confirmation hearings, he was asked about this apparent sweetheart deal and testified that the shares “were available to every single individual that was an investor at the time.”

Grimaldi’s reporting says that’s false.

“In fact,” he reports “the cabinet nominee was one of fewer than 20 U.S. investors who were invited last year to buy discounted shares of the company—an opportunity that, for Mr. Price, arose from an invitation from a company director and fellow congressmen.”